Biomx

Biomx CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Biomx (PHGE) as of Oct 26, 2026 is -0.01 %. In the previous year, CapEx to Operating Cash Flow Ratio was -0.08 % — a change of -90.66% (higher).

CapEx/OCF

-0.01 %

YoY

-90.66%

Last updated:

CapEx to Operating Cash Flow Ratio of Biomx is 2025 -0.01 % . CapEx to Operating Cash Flow Ratio of Biomx was 2024 -0.08 % . It decreases by -90.66% higher compared to the previous year.

The Biomx CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
0.00 USD
Jan 1, 2019
-7.46 USD
Jan 1, 2020
-4.13 USD
Jan 1, 2021
-13.35 USD
Jan 1, 2022
-0.38 USD
Jan 1, 2023
-0.23 USD
Jan 1, 2024
-0.08 USD
Jan 1, 2025
-0.01 USD
The Biomx CapEx/OCF history
YEARCapEx/OCFYoY
-0.01 %-90.66%
-0.08 %-65.46%
-0.23 %-38.99%
-0.38 %-97.12%
-13.35 %+223.54%
-4.13 %-44.71%
-7.46 %—
0.00-100.00%
-20.73 %+182.63%
-7.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomx Stock analysis

What does Biomx do? BiomX Ltd develops bacteriophage-based therapies targeting dysbiosis-related diseases, focusing on natural and engineered phage solutions. The company's pipeline includes BX001 for acne-prone skin, BX002 for IBD bacterial targets, and BX003 for Klebsiella pneumoniae strains. BiomX discovers and validates bacterial targets to customize phage compositions, aiming to treat conditions like inflammatory bowel disease, primary sclerosing cholangitis, and cancer through targeted bacterial destruction. The firm creates therapies for skin appearance issues and chronic diseases, with BX001 addressing acne, BX002 targeting IBD onset bacteria, and BX003 focusing on specific Klebsiella pneumoniae strains. BiomX's approach involves developing both natural and engineered phage cocktails tailored to bacterial targets, ensuring precise treatment for microbiome-related conditions without naming specific buyers or segments. BiomX Ltd's revenue model relies on the development and commercialization of its phage therapy pipeline. The company's products BX001, BX002, and BX003 are designed to treat specific bacterial-related conditions, with BX001 targeting skin appearance, BX002 for IBD, and BX003 for Klebsiella pneumoniae, all developed through customized phage compositions against validated bacterial targets. Biomx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomx stock

CapEx to Operating Cash Flow Ratio of Biomx is -0.01 % in 2025.

CapEx to Operating Cash Flow Ratio of Biomx changed from -0.08 % to -0.01 %, representing a -90.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Biomx since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Biomx with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biomx

All Key Metrics — Biomx